OKI-179

October, 2020

Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. 24 October – 25 October 2020


October, 2019

OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. 25 October – 30 October 2019


August, 2019

Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas

Cancer Immunol Res: 7(8) August 2019. doi: 10.118/2236-6066. CIR-18-0875


June, 2019

Could inhibiting both HDAC and PD-1 improve immuno-oncology treatments?

NEWS Provided by Fierce Biotech


OKI-422

January, 2020

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Mondello et al., Cancer Discov 2020;10:440–59; doi: 10.1158/2159-8290.CD-19-0116

Note OKI-422 = BRD3308


January, 2017

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

Jiang et al., Cancer Discov. 2017 Jan;7(1):38-53; doi: 10.1158/2159-8290.CD-16-0975

Note OKI-422 = HDAC3 inhibitor


February, 2016

An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β‑Cell Protection

Wagner et al., ACS Chem Biol. 2016 Feb 19;11(2):363-74; doi: 10.1021/acschembio.5b00640

Note OKI-422 = BRD3308